The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis

European Journal of Cancer

Volumn 48, Issue 3, 2012, Pages 340-346

  Gomez Fernandez, Cristina ^a   Garden, Benjamin C ^b   Wu, Shenwong ^c   Feldman, Darren R ^b   Lacouture, Mario E ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Cancer; mTOR inhibitor; Renal cell carcinoma; Skin rash; Stomatitis; Temsirolimus

Indexed keywords

ALPHA INTERFERON; TEMSIROLIMUS;

DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; ERYTHEMA; HUMAN; INCIDENCE; KIDNEY CARCINOMA; LUNG SMALL CELL CANCER; MANTLE CELL LYMPHOMA; META ANALYSIS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RASH; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; SKIN EDEMA; SKIN ULCER; SOFT TISSUE SARCOMA; STOMATITIS; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; EXANTHEMA; HUMANS; INCIDENCE; PROTEIN KINASE INHIBITORS; RISK FACTORS; SIROLIMUS; STOMATITIS;

EID: 84856212971     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.11.028     Document Type: Article

References (28)

1. A. Fasolo, and C. Sessa Current and future directions in mammalian target of rapamycin inhibitors development Expert Opin Investig Drugs 20 3 2011 381 394
2. Torisel package insert: http://www.torisel.com/.
3. R.T. Abraham, and J.J. Gibbons The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy Clin Cancer Res 13 2007 3109 3114 (Pubitemid 46944891)
4. D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell 12 2007 9 22 (Pubitemid 47001784)
5. Coppin C, Le L, Porzsolt F, Wilt T. Targeted therapy for advanced renal cell Carcinoma. Cochrane Database Syst Rev 2008;2:CD006017.
6. Staehler M, Haseke N, Khoder W, Stief CG. Profile of temsirolimus in the treatment of advanced renal cell carcinoma. Onco Targets Ther 2010;3:191-6.
7. S.A. Soefje, A. Karnad, and A.J. Brenner Common toxicities of mammalian target of rapamycin inhibitors Target Oncol 6 2 2011 Jun 125 129
8. A.L. Watters, J.B. Epstein, and M. Agulnik Oral complications of targeted cancer therapies: a narrative literature review Oral Oncol 47 6 2011 441 448
9. Ansell SM, Inwards DJ, Rowland KM Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008;113(3):508-14.
10. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779;a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22(5):909-18. (Pubitemid 41103603)
11. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95(9):1148-54. (Pubitemid 44660065)
12. S.S. Farag, S. Zhang, and B.S. Jansak Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma Leuk Res 33 11 2009 1475 1480
13. H. Gerullis, L. Bergmann, L. Maute, C. Eimer, and T. Otto Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany Cancer Chemother Pharmacol 63 6 2009 May 1097 1102
14. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81. (Pubitemid 46849157)
15. Okuno S, Bailey H, Mahoney MR, et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the mayo phase 2 consortium (P2C). Cancer 2011;117(15):3468-75. doi: 10.1002/cncr.25928.
16. K.J. Pandya, S. Dahlberg, and M. Hidalgo A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500) J Thorac Oncol 2 11 2007 1036 1041 (Pubitemid 350059580)
17. Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol 2010;28(31):4740-6.
18. Goodwin RA, Jamal R, Tu D, et al. Temsirolimus (TEM) in endometrial cancer: predictors of response and progression. J Clin Oncol 2010;28(suppl.; abstr. 3090):15s.
19. M. Gandhi, T. Kuzel, and M. Lacouture Eosinophilic rash secondary to temsirolimus Clin Genitourin Cancer 7 2 2009 E34 E36
20. T.E. Hutson, R.A. Figlin, J.G. Kuhn, and R.J. Motzer Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies Oncologist 13 10 2008 1084 1096
21. Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant 2010;24(2):149-56.
22. Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010;116(1):210-5.
23. P.A. Creel Management of mTOR inhibitor side effects Clin J Oncol Nurs 13 Suppl. 2009 19 23
24. Worthington HV, Clarkson JE, Bryan G, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2011;4:CD000978.
25. T.J. Lynch Jr., E.S. Kim, and B. Eaby Epidermal growth factor receptor inhibitor associated cutaneous toxicities: an evolving paradigm in clinical management Oncologist 12 2007 610 621 (Pubitemid 350012125)
26. J. Autier, B. Escudier, J. Wechsler, A. Spatz, and C. Robert Prospective study of the cutaneous effects of sorafenib, a novel multikinase inhibitor Arch Dermatol 144 2008 886 892 (Pubitemid 352039741)
27. K.Y. Tsai, C.H. Yang, T.T. Kuo, H.S. Hong, and J.W. Chang Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma J Clin Oncol 24 2006 5786 5788 (Pubitemid 46631323)
28. S. Kim, P. Wong, and P. Coulombe A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth Nature 441 2006 362 365 (Pubitemid 44050202)